Changxing People's Hospital
Changxing People's Hospital
Explore linked clinical trials.7 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery Disease | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2026-08-27 | NCT06218485 | |
| Routine Angiography Follow-Up After Percutaneous Coronary Intervention in High-Risk Patients | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Recruiting | Not applicable | 2026-08-21 | NCT05923489 | |
| Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica | Polymyalgia Rheumatics (PMR) | Not yet recruiting | Not applicable | 2025-12-05 | NCT07266168 | |
| Clinical Study of Single Incision Laparoscopic Cholecystectomy in the Treatment of Patients With Acute Cholecystitis | Cholecystectomy, Laparoscopic | Recruiting | Not applicable | 2024-11-21 | NCT06074679 | |
| Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease | Arterial Occlusive Diseases, arteriosclerosis disorder, cardiovascular disorder, coronary artery disorder, heart disorder, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2024-01-23 | NCT04397211 | |
| Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases | PMMR/Ras/BRAF Wild-type; Unresectable Colon Cancer Peritoneal Metastases | Recruiting | Phase 2 | 2023-02-24 | NCT05742425 | |
| Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer | HER2-negative Breast Cancer; Neoadjuvant Chemotherapy | Recruiting | Phase 2 / Phase 3 | 2021-08-12 | NCT04576143 |